Director's Dealing • Mar 5, 2025
Director's Dealing
Open in ViewerOpens in native device viewer
Oncoinvent ASA: Mandatory notification of trade
Oncoinvent ASA ("Oncoinvent" or the "Company") Primary insider Anne Cecile Alvik, Head of QA and Board member (employee representative) of Oncoinvent ASA, has 5. March 2025 acquired 8 500 shares in Oncoinvent ASA at an average price of NOK 1,694 per share. Following this transaction, Anne Cecilie owns 13 200 shares in Oncoinvent ASA.
This information is subject to the disclosure requirements pursuant to article 19 of the regulation EU 596/2014 (the EU Market Abise Regulation) and section 5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver powerful radiation directly to cancer cells. The Company’s lead product candidate, Radspherin®, is being advanced through clinical development by a team with experience from all stages of radiopharmaceutical development. Internal manufacturing and supply chain capabilities have been established, which now have the capacity to supply Radspherin® for multi-center phase 2 clinical studies.
For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: [email protected]
Tore Kvam, Chief Financial Officer
Email: [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.